Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feiyan Qinghua Decoction (FYQHD) is a traditional Chinese medicine formula derived from the classical Ma Xing Shi Gan decoction, originally documented in Zhang Zhong Jing’s "Treatise on Exogenous Febrile Disease" during the Han Dynasty. FYQHD consists of nine herbal ingredients and has been used clinically for decades to treat pneumonia and infectious diseases such as sepsis and influenza. Mechanistically, FYQHD exerts its effects by inhibiting hyperinflammation—specifically through suppression of the HMGB1/RAGE signaling pathway and PI3K/AKT/mTOR/4E-BP1 axis—thereby reducing pro-inflammatory cytokine production (e.g., TNF-α, IL-6, MCP-1). It also enhances immune defense by promoting macrophage phagocytosis via upregulation of receptors like CD169 and SR-A1. In models of influenza infection, FYQHD modulates gut microbiota composition to increase short-chain fatty acid (SCFA) production (notably acetate), which boosts type I interferon responses and restores intestinal barrier integrity. These combined actions result in reduced pathogen load, improved survival rates in sepsis models, attenuation of lung injury from viral infections, and overall enhanced host antiviral immunity[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on feiyan qinghua decoction.